A Phase I Trial of the IGF-1R Antibody AMG 479 in Combination With Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer (The RAP Trial).
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Everolimus (Primary) ; Ganitumab (Primary) ; Panitumumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Biomarker
- Acronyms QUILT-3.007; RAP
- 09 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Feb 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 09 Feb 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.